LOBEF Stock — Lobe Sciences Ltd

Lobe Sciences Ltd (LOBEF)

Updated October 16, 2026.

LOBEF is a Stock. Total return is 8200.0% over the past 7 years, 8013.4 points ahead of SPY at 186.6%.

Lobe Sciences Ltd. is a biopharmaceutical company developing lipid-based treatments for orphan and rare diseases, with a focus on products like Altemia® MF, a medical food for managing deficiencies in sickle cell disease. The company was founded in 2018 and is headquartered in Vancouver, Canada. There is no established distribution schedule for this equity security.

LOBEF performance versus SPY

Price and return data through 2026-10-16.

Total return is 8200.0% over the past 7 years, 8013.4 points ahead of SPY at 186.6%. Over the past year its total return — price change plus distributions reinvested — is 906.1%. Its deepest 1-year drawdown was 94.2%.

LOBEF key facts

Asset type

Stock

Asset class

Equity

Distribution frequency

None

Last close

$0.03 (as of 2026-10-16)

Market cap

$10,231,648

Average volume

1502.0

Beta

0.179

Payout ratio

0.0%

EPS

$-0.03

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LOBEF risks and drawbacks

The deepest 1-year drawdown on record here is 94.2%.

Who may consider LOBEF — and who may not

It is a weaker fit for investors who need monthly cash flow (LOBEF does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on LOBEF

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions